zealand_logo_RGB_01.png
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
21 sept. 2022 08h15 HE | Zealand Pharma
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) ...
zealand_logo_RGB_01.png
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
19 sept. 2022 02h00 HE | Zealand Pharma
Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma grants warrants to employees in Denmark
13 sept. 2022 16h05 HE | Zealand Pharma
Company announcement – No. 40 / 2022 Zealand Pharma grants warrants to employees in Denmark Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
08 sept. 2022 16h05 HE | Zealand Pharma
Company announcement – No. 39 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, September 8, 2022 – Zealand Pharma...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
07 sept. 2022 11h00 HE | Zealand Pharma
Press release – No. 4/ 2022 Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Copenhagen, DK and Boston, MA, September 7, 2022 – Zealand Pharma A/S (Nasdaq...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
07 sept. 2022 02h00 HE | Zealand Pharma
Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Total number of shares and voting rights in Zealand Pharma at August 31, 2022
31 août 2022 15h30 HE | Zealand Pharma
Company announcement – No. 37 / 2022 Total number of shares and voting rights in Zealand Pharma at August 31, 2022 Copenhagen, DK and Boston, MA, August 31, 2022 – Zealand Pharma A/S (“Zealand”)...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer
24 août 2022 04h30 HE | Zealand Pharma
COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
18 août 2022 14h58 HE | Zealand Pharma
Company announcement – No. 35 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, August 18, 2022 – Zealand Pharma A/S...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma Announces Financial Results for the First Half of 2022
11 août 2022 09h00 HE | Zealand Pharma
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK and Boston, MA, U.S. August 11, 2022 – Zealand...